AC
REGN icon

Avestar Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Avestar Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$509K Buy
659
+24
+4% +$18.4K 0.03% 349
2025
Q4 		$490K Sell
635
-295
-32% -$200K 0.03% 342
2025
Q3 		$523K Buy
930
+420
+82% +$237K 0.03% 332
2025
Q2 		$268K Sell
510
-164
-24% -$91.5K 0.02% 410
2025
Q1 		$427K Sell
674
-113
-14% -$77.7K 0.04% 315
2024
Q4 		$561K Buy
787
+64
+9% +$53.7K 0.05% 264
2024
Q3 		$760K Buy
723
+52
+8% +$57.9K 0.08% 196
2024
Q2 		$705K Sell
671
-17
-2% -$16.5K 0.07% 197
2024
Q1 		$662K Buy
688
+323
+88% +$307K 0.07% 201
2023
Q4 		$321K Buy
+365
New +$301K 0.04% 282
2019
Q3 		– Sell
-78
Closed -$21K – 685
2019
Q2 		$21K Sell
78
-7
-8% -$2.33K 0.01% 388
2019
Q1 		$33K Sell
85
-209
-71% -$86.1K 0.02% 329
2018
Q4 		$87K Sell
294
-54
-16% -$19.8K 0.06% 197
2018
Q3 		$122K Buy
348
+57
+20% +$21.7K 0.07% 175
2018
Q2 		$85K Buy
291
+26
+10% +$8.13K 0.05% 217
2018
Q1 		$77K Buy
265
+92
+53% +$32K 0.05% 204
2017
Q4 		$45K Buy
+173
New +$70.1K 0.03% 261

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Avestar Capital's REGN Position: Q1 2026 in Review

Avestar Capital increased its Regeneron Pharmaceuticals (REGN) stake by 3.8% in Q1 2026, buying an estimated $18.4K and bringing the position to 659 shares worth $509K. The position accounts for 0.03% of the portfolio, ranked #349.

Avestar Capital first reported a position in REGN in Q4 2017 and has held it in 17 quarters since. The position peaked at $760K in Q3 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Avestar Capital held 659 shares of Regeneron Pharmaceuticals worth $509K as of Q1 2026.
  • Avestar Capital bought 24 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $18.4K.
  • Regeneron Pharmaceuticals made up 0.03% of Avestar Capital's portfolio in Q1 2026, its #349 holding.
  • Avestar Capital first reported a position in Regeneron Pharmaceuticals in Q4 2017 and has held it in 17 quarters since.
  • Avestar Capital's Regeneron Pharmaceuticals position peaked at $760K in Q3 2024.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Avestar Capital's 13F filing for Q1 2026, filed 13 May 2026.